April 24, 2014 6:32 PM ET


Company Overview of Shire Pharmaceuticals, Inc.

Company Overview

Shire Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling pharmaceutical products. It focuses on central nervous system, gastrointestinal, general products, renal diseases, and human genetic therapies. The company offers ADDERALL and ADDERALL XR for attention deficit hyperactivity disorder (ADHD); REMINYL for Alzheimer's; and CARBATROL for epilepsy. It also develops a range of treatments for ADHD to treat children, adolescents, and adults, as well as researches on non-scheduled compounds. The company markets its products to defined customer groups, such as specialist doctors. It has sales and marketing infrastructure with a portfolio of products targeting the U...

725 Chesterbrook Boulevard

Wayne, PA 19087

United States

Founded in 2004





Key Executives for Shire Pharmaceuticals, Inc.

Shire Pharmaceuticals, Inc. does not have any Key Executives recorded.

Shire Pharmaceuticals, Inc. Key Developments

Shire Pharmaceuticals, Inc. Presents at 19th Annual BIO-Europe International Partnering Conference, Nov-04-2013 03:45 PM

Shire Pharmaceuticals, Inc. Presents at 19th Annual BIO-Europe International Partnering Conference, Nov-04-2013 03:45 PM. Venue: Messe Wien Exhibition and Congress Center, Vienna, Austria. Speakers: Charlie Alexander, Senior Director, Business Development.

Massachusetts Institute of Technology Accuses Shire Pharmaceuticals and Shire Regenerative Medicine's Dermagraft of Infringing Skin Growth Patents

Shire Pharmaceuticals, Inc. and its Advanced BioHealing, Inc. (Shire Regenerative Medicine) are facing civil charges of violating patents held by the Massachusetts Institute of Technology and Children's Medical Center Corporation (CCMC) in marketing a diabetic foot ulcer treatment. The case, filed in Massachusetts district court Jan. 4, involves three 1998 patents describing techniques to attach living human cells to a mesh that can then be implanted to regrow skin tissue. Dermagraft consists of a bioabsorbable mesh scaffold that can be seeded with human fibroblast cells, which grow on the scaffold, secreting collagen and other substances. The result is a three-dimensional skin substitute made of living cells, according to the complaint. The FDA approved the device in 2001 to treat full-thickness diabetic foot ulcers. MIT and CCMC initially licensed the technologies to Advanced Tissue Sciences, which obtained Dermagraft's approval and launched the product in the market. When the company went out of business in 2006, Dermagraft was sold to Advanced BioHealing. Shire acquired Advanced BioHealing in 2011, renaming the division Shire Regenerative Medicine the following year. MIT attempted to discuss the licensing arrangement with Shire after that purchase, but received no response, according to the lawsuit. The complaint charges Shire with three counts of knowingly infringing on the MIT and CCMC patents. The plaintiffs which have requested a jury trial are seeking damages, attorney fees, and unspecified further relief.

Shire Pharmaceuticals, Inc. Presents at Science, Partner, and Investment Forum 2012, May-21-2012 10:10 AM

Shire Pharmaceuticals, Inc. Presents at Science, Partner, and Investment Forum 2012, May-21-2012 10:10 AM. Venue: Palm Beach County Convention Center, West Palm Beach, Florida, United States. Speakers: Gwen Melincoff, Senior Vice President, Business Development.

Similar Private Companies By Industry

Company Name Region
Labopharm USA, Inc. United States
American Cyanamid Agricultural Research Division United States
Riogin Corporation United States
Metabolic Maintenance Products, Inc. United States
ApopLogic Pharmaceuticals LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Shire Pharmaceuticals, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.